Alison Stopeck, MD, and Patricia Thompson, PhD, have been awarded $1.7 million by the National Cancer Institute to study NSAID effects on clinical and imaging breast biomarkers.
Dr. Stopeck is the director of the University of Arizona Cancer Center's Breast Cancer program and Dr. Thompson leads the UACC's Cancer Prevention and Control program. In addition, Dr. Stopeck is a professor of medicine and Dr. Thompson is an associate professor of cellular and molecular medicine at the University Of Arizona College of Medicine.
This grant will go toward studying the potentially potent efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) for the anti-cancer activity in breast cancer models, with observational evidence that supports lower odds of breast cancer recurrences among regular users.
The researchers will use magnetic resonance imaging (MRI) and tissue biomarker studies to specifically assess the effect of sulindac (a potent, non-selective NSAID) in combination with aromatase inhibitors on "high-risk" breast tissue of women with estrogen receptor positive breast cancers, which comprise the majority of breast cancer cases.
This study is supported by grant number CA161534 from the National Cancer Center of the National Institutes of Health.
-Aug. 9, 2012